2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
184
HER2-positive Breast Cancer
18
Neoplasms
13
Neoplasm Metastasis
11
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
pertuzumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled